Journal
MOLECULAR THERAPY-ONCOLYTICS
Volume 13, Issue -, Pages 1-6Publisher
CELL PRESS
DOI: 10.1016/j.omto.2019.02.001
Keywords
-
Categories
Ask authors/readers for more resources
Platinum-based chemotherapy has long been the first-line treatment of choice for metastatic non-small-cell lung cancer (NSCLC) patients who lack targetable gene mutations. The arrival of checkpoint blockade has led to a vast shift in the treatment landscape of NSCLC. Among NSCLC patients with PD-L1 expression in >= 50% of tumor cells, treatment with pembrolizumab leads to a superior progression-free and overall survival compared to platinum-doublet chemotherapy in the first-line setting. Furthermore, the addition of pembrolizumab to standard chemotherapy of pemetrexed and a platinum-based drug resulted in significant longer progression-free survival and overall survival irrespective to PD-Ll expression. In this review, we focus on the molecular rationale for the combination therapy and the results of completed clinical studies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available